Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1440

1.

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.

Clin Cancer Res. 2006 Oct 1;12(19):5869-78.

2.

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.

Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K.

Blood. 2006 Jul 15;108(2):645-52. Epub 2006 Mar 14.

3.

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.

Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R.

Mol Cancer Ther. 2007 Apr;6(4):1400-5.

4.
5.

Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.

Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, Kolhe R, Balusu R, Eaton K, Lee P, Ustun C, Jillella A, Buser CA, Peiper S, Bhalla K.

Clin Cancer Res. 2008 Oct 1;14(19):6106-15. doi: 10.1158/1078-0432.CCR-08-0721.

6.

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.

Nguyen TK, Rahmani M, Harada H, Dent P, Grant S.

Blood. 2007 May 1;109(9):4006-15. Epub 2007 Jan 11.

8.

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K.

Blood. 2005 Feb 15;105(4):1768-76. Epub 2004 Oct 28.

11.

Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.

Cancer Res. 2003 Aug 15;63(16):5126-35.

12.
13.

Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.

Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.

Cancer Res. 2003 May 1;63(9):2118-26.

14.

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.

Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R.

Cancer Res. 2008 Dec 1;68(23):9624-33. doi: 10.1158/0008-5472.CAN-08-1131.

15.

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.

Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, Grant S.

Blood. 2008 Aug 1;112(3):793-804. doi: 10.1182/blood-2007-10-116376. Epub 2008 May 27.

16.

PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S.

Clin Cancer Res. 2013 Jan 15;19(2):404-14. doi: 10.1158/1078-0432.CCR-12-2799. Epub 2012 Nov 30.

17.

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S.

Clin Cancer Res. 2011 May 15;17(10):3219-32. doi: 10.1158/1078-0432.CCR-11-0234. Epub 2011 Apr 7.

18.
19.

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.

Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, Flefleh C, Castaneda S, Inigo I, Kan D, Wen ML, Kramer R, Blackwood-Chirchir A, Lee FY.

Clin Cancer Res. 2006 Dec 1;12(23):7180-6.

20.

Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.

Okabe S, Tauchi T, Ohyashiki K.

Clin Cancer Res. 2008 Oct 1;14(19):6181-6. doi: 10.1158/1078-0432.CCR-08-0461.

Supplemental Content

Support Center